Visual performance and patient preference with bilateral implantation of an extended depth of focus or combined implantation of an extended depth of focus/trifocal intraocular lens.

"Declarations Conflict of interestFK, JM, and JO have received research support from Carl Zeiss Meditec, AG. FK and JM have received speaker and consultant honoraria from Carl Zeiss Meditec, Inc. FK has also served on advisory boards for Carl Zeiss Meditec, Inc. Conflict of interest FK, JM, and JO have received research support from Carl Zeiss Meditec, AG. FK and JM have received speaker and consultant honoraria from Carl Zeiss Meditec, Inc. FK has also served on advisory boards for Carl Zeiss Meditec, Inc."

"Funding This study was sponsored and funded by Carl Zeiss Meditec, Inc., USA."

"This study was carried out in compliance with EN ISO 14155:2012-01 Clinical Investigation of Medical Devices for Human Subjects, German Medical device law (Medical Devices Act—MPG) §23 b, MPSV—Ordinance on the Registration, Evaluation and Prevention of Risks of Medical Devices (Medical Devices Safety Plan Ordinance). The study was conducted in accordance with the ethics principles of the Declaration of Helsinki, and all patients provided informed consent. The study was approved by all local ethics committees and was retrospectively registered on clinicaltrials.gov (#NCT05462067). Methods: Multicentered, comparative, open-label, retrospective/prospective study. Post-IOL implantation, patients were prospectively enrolled into this study; preoperative patient data were collected retrospectively. Follow-up was at 2–4 and 5–8 months post-surgery. The primary endpoint was binocular best corrected distance visual acuity (CDVA). The study was retrospectively registered on clinicaltrials.gov (#NCT05462067)."